Biodexa Pharmaceuticals Plc (BDRX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 83K | 298K | 231K | 468K | 177K | 401K | 175K | 168K |
| Revenue Growth % | - | - | -100% | -100% | -64.07% | -36.32% | 30.51% | 16.71% | 1.14% | 138.69% | -21.17% | -62.83% |
| Cost of Goods Sold | 48.7K | 1.67M | 3.25M | 2.19M | 2.25M | 2.25M | 2.7M | 2.41M | 2.64M | 2.01M | 3.82M | 3.99M |
| COGS % of Revenue | - | - | - | - | 2712.05% | 755.37% | 1167.97% | 515.6% | 1493.79% | 501.25% | 2182.29% | 2374.4% |
| Gross Profit | -48.7K | -1.67M | -3.25M | -2.19M | -2.17M | -1.95M | -2.47M | -1.95M | -2.47M | -1.61M | -3.64M | -3.82M |
| Gross Margin % | - | - | - | - | -2612.05% | -655.37% | -1067.97% | -415.6% | -1393.79% | -401.25% | -2082.29% | -2274.4% |
| Gross Profit Growth % | 98.5% | 23.94% | -49.82% | -12.08% | 12.12% | -0.41% | 0% | -20.88% | 32.3% | 57.89% | 12.45% | -27.07% |
| Operating Expenses | 4.68M | 2.35M | 1.73M | 4.22M | 1.6M | 1.9M | 2.62M | 1.44M | 227K | 1.76M | 1.96M | 14.02M |
| OpEx % of Revenue | - | - | - | - | 1930.12% | 639.26% | 1132.9% | 306.62% | 128.25% | 438.65% | 1117.14% | 8343.45% |
| Selling, General & Admin | 2.46M | 2.38M | 1.76M | 2.03M | 741K | 2.29M | 1.33M | 1.85M | 1.29M | 1.66M | 2.75M | 2.93M |
| SG&A % of Revenue | - | - | - | - | 892.77% | 768.79% | 577.06% | 395.09% | 728.81% | 412.97% | 1568.57% | 1745.83% |
| Research & Development | 2.28M | 1.67M | 3.25M | 2.19M | 1.82M | 2.25M | 2.7M | 2.41M | 2.64M | 2.01M | 12.16M | 3.99M |
| R&D % of Revenue | - | - | - | - | 2187.95% | 755.37% | 1167.97% | 515.6% | 1493.79% | 501.25% | 6946.86% | 2374.4% |
| Other Operating Expenses | -63.85K | -1000K | -1000K | 0 | -955K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4.72M | -4.02M | -4.98M | -4.22M | -3.77M | -4.24M | -3.79M | -3.78M | -3.76M | -3.23M | -6.38M | -6.75M |
| Operating Margin % | - | - | - | - | -4542.17% | -1424.16% | -1642.42% | -807.26% | -2126.55% | -806.48% | -3644% | -4020.24% |
| Operating Income Growth % | 5.05% | 4.9% | -31.99% | 0.49% | 0.63% | -12.33% | -0.8% | -16.82% | 40.98% | 52.12% | -4.99% | -28.79% |
| EBITDA | -4.68M | -3.94M | -4.93M | -4.09M | -3.7M | -4.17M | -3.71M | -3.68M | -3.67M | -3.12M | -5.75M | -6.28M |
| EBITDA Margin % | - | - | - | - | -4454.22% | -1399.66% | -1607.36% | -786.75% | -2072.32% | -777.31% | -3286.86% | -3738.1% |
| EBITDA Growth % | 5.09% | 3.47% | -33.27% | 2.01% | 0.43% | -13.28% | -1.23% | -18.13% | 36.23% | 50.37% | -8.39% | -32.88% |
| D&A (Non-Cash Add-back) | 48.7K | 71K | 49K | 136K | 73K | 73K | 81K | 96K | 96K | 117K | 625K | 474K |
| EBIT | -4.72M | -4.02M | -4.98M | -3.38M | -2.36M | -4.24M | -3.79M | -3.78M | -3.76M | -3.23M | -6.38M | -6.75M |
| Net Interest Income | 32.8K | -100K | -37K | 39K | 40K | 2K | 6K | 18K | 22K | 22K | 12K | 21K |
| Interest Income | 53.67K | 0 | 0 | 88K | 40K | 2K | 6K | 18K | 22K | 22K | 12K | 21K |
| Interest Expense | 20.87K | 100K | 37K | 49K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 2.22M | 45K | 2.43M | 790K | 141K | 388K | 64K | 380K | 1.05M | -156K | -916K | 486K |
| Pretax Income | -2.5M | -3.97M | -2.55M | -3.43M | -3.63M | -3.86M | -5.09M | -3.4M | -2.72M | -3.39M | -5.61M | -17.86M |
| Pretax Margin % | - | - | - | - | -4372.29% | -1293.96% | -2203.46% | -726.07% | -1534.46% | -845.39% | -3206.29% | -10630.36% |
| Income Tax | 59.63K | 165K | -125K | -125K | -118K | -288K | -495K | -337K | -410K | -236K | -842K | -439K |
| Effective Tax Rate % | -2.38% | -4.16% | 4.91% | 3.64% | 3.25% | 7.47% | 9.72% | 9.92% | 15.1% | 6.96% | 15.01% | 2.46% |
| Net Income | -2.56M | -3.81M | -2.42M | -3.31M | -3.51M | -3.57M | -4.59M | -3.06M | -2.31M | -3.15M | -4.77M | -17.42M |
| Net Margin % | - | - | - | - | -4230.12% | -1197.32% | -1989.18% | -654.06% | -1302.82% | -786.53% | -2725.14% | -10369.05% |
| Net Income Growth % | -5.83% | -15.05% | 31.05% | 7.29% | 23.59% | -16.56% | -99.26% | 2.95% | 51.65% | 81.89% | -1.06% | -294.21% |
| Net Income (Continuing) | -2.56M | -4.14M | -2.42M | -3.31M | -3.51M | -3.57M | -4.59M | -3.06M | -2.31M | -3.15M | -4.77M | -17.42M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.00 | -999999.00 | -365000.00 | -792000.00 | -113000.00 | -219000.00 | -999999.00 | -999999.00 | -999999.00 | -999999.00 | -999999.00 | -999999.00 |
| EPS Growth % | 100% | -90.15% | -223.01% | -261.64% | 96.19% | 88.92% | -99.26% | 2.95% | 51.64% | 96.38% | 83.17% | 60.59% |
| EPS (Basic) | 0.00 | -999999.00 | -365000.00 | -792000.00 | -113000.00 | -219000.00 | -999999.00 | -999999.00 | -999999.00 | -999999.00 | -999999.00 | -999999.00 |
| Diluted Shares Outstanding | 225.82K | 252.67K | 61.95K | 2.48K | 30 | 7 | 1 | 1 | 1 | 1 | 1 | 0 |
| Basic Shares Outstanding | 225.82K | 252.67K | 61.95K | 2.48K | 30 | 7 | 1 | 1 | 1 | 1 | 1 | 0 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |